Debates over selective serotonin reuptake inhibitors (SSRIs) persist due to conflicting evidence about their effectiveness, side effects, and long-term impacts on mental health. While widely prescribed for conditions like depression and anxiety, questions remain about their true benefits compared to placebos and their potential risks, including emotional numbness or withdrawal symptoms. Critics argue over whether the pharmaceutical industry’s influence has skewed research, while advocates highlight their role in saving lives for those struggling with severe mental illness. The ongoing tension reflects broader challenges in balancing medical progress with ethical concerns about treatment transparency and patient autonomy.
Opinion | Why We Can’t Stop Arguing About S.S.R.I.s The New York Times
